Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

被引：211

作者：

Martin, AM ^{[1
]}

Nolan, D

James, I

Cameron, P

Keller, J

Moore, C

Phillips, E

Christiansen, FT

Mallal, S

机构：

[1] Royal Perth Hosp, Ctr Clin Immunol & Biomed Stat, Perth, WA, Australia

[2] Murdoch Univ, Perth, WA, Australia

[3] Royal Perth Hosp, Dept Clin Immunol & Biochem Genet, Perth, WA, Australia

[4] Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Clin Pharmacol, Toronto, ON, Canada

[5] Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Infect Dis, Toronto, ON, Canada

[6] Univ Western Australia, Sch Surg & Pathol, Nedlands, WA 6009, Australia

来源：

AIDS | 2005年 / 19卷 / 01期

关键词：

D O I：

10.1097/00002030-200501030-00014

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Genetic (human leukocyte antigen), disease-related and demographic risk factors for nevirapine reactions were examined in a nevirapine-exposed cohort. Cases involving combinations of hepatitis, fever or rash were associated with an interaction between HLA-DRB1*0101 and the percentage of CD4, whereas no associations were detected for isolated rash. These data suggest that HLA-DRB1*0101 and the CD4 status may determine susceptibility to nevirapine hypersensitivity, consistent with a CD4 T-cell-dependent immune response to nevirapine-specific antigens.

引用

页码：97 / 99

页数：3

共 5 条

[1]

*BOEHR ING PHARM I, 2003, VIR PACK INS

[2] Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors [J].

Dieterich, DT ;

Robinson, PA ;

Love, J ;

Stern, JO .

CLINICAL INFECTIOUS DISEASES, 2004, 38 :S80-S89

[3] Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir [J].

Mallal, S ;

Nolan, D ;

Witt, C ;

Masel, G ;

Martin, AM ;

Moore, C ;

Sayer, D ;

Castley, A ;

Mamotte, C ;

Maxwell, D ;

James, I ;

Christiansen, FT .

LANCET, 2002, 359 (9308) :727-732

[4] Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals [J].

Patel, SM ;

Johnson, S ;

Belknap, SM ;

Chan, J ;

Sha, BE ;

Bennett, C .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 35 (02) :120-125

[5] A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients [J].

Stern, JO ;

Robinson, PA ;

Love, J ;

Lanes, S ;

Imperiale, MS ;

Mayers, DL .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 34 :S21-S33

← 1 →